-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the information published by the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China, BPI-16350 Capsules of Betta Pharmaceuticals has obtained two clinical trials implied licenses and plans to develop treatments for breast cancer
.
Public information shows that BPI-16350 is a CDK4/6 inhibitor under development and belongs to a class 1 new drug.
Screenshot source: CDE official website
According to the announcement of Betta Pharmaceuticals, BPI-16350 is a CDK4/6 inhibitor independently developed by the company.